<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366043">
  <stage>Registered</stage>
  <submitdate>24/03/2014</submitdate>
  <approvaldate>3/04/2014</approvaldate>
  <actrnumber>ACTRN12614000356662</actrnumber>
  <trial_identification>
    <studytitle>The effect of ivacaftor (VX-770, registered in Australia as Kalydeco) on exocrine pancreatic function in patients 6 years 
and older with cystic fibrosis and at least one copy of the G551D CFTR mutation and who are naive for ivacaftor
</studytitle>
    <scientifictitle>The effect of ivacaftor (VX-770, registered in Australia as Kalydeco) on exocrine pancreatic function in patients 6 years 
and older with cystic fibrosis and at least one copy of the G551D CFTR mutation and who are naive for ivacaftor
</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Kalydeco (ivacaftor) 150mg administered orally twice daily for 34 weeks. Tablet counts will be used to assess adherence to study medicine dosage.</interventions>
    <comparator>nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Exocrine Pancreatic Function as measured by faecal fat excretion</outcome>
      <timepoint>Assessed at baseline at 16 weeks and at 34 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>body weight measured by scales</outcome>
      <timepoint>every 4 weeks from Visit 1 to Visit 10</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Participants 6 years and older with cystic fibrosis and at least one copy of the G551D CFTR mutation, requiring pancreatic enzyme replacement therapy and who are naive for ivacaftor
</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. known hypersensitivity to ivacaftor, its metabolites, or formulation excipients

2. galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

3. have undergone organ transplantation

4.Use of any inhibitors (itraconazole, posaconazole, voriconazole, ketoconazole, telithromycin, clarithromycin) or inducers of (rifampicin, rifabutin, phenobarbital, carbamazepine, phenytoin, St Johns Wort) CYP450 3A, within 14 days prior to the first dose of ivacaftor or during the study period 

5. hepatic insufficiency defined as Child-Pugh Class C impairment (a score of 10)

6. severe renal impairment, as defined by creatinine clearance less than or equal to 30mL/min or end stage renal disease

7. Pregnant, planning a pregnancy during the course of the study , or breast-feeding 
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Observational - no sample size calculation performed as this is a Phase IV study and sufficient medication for 20 participants only has been provided due to the very high cost of the medication </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>3/03/2014</anticipatedstartdate>
    <actualstartdate>24/03/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Enrolling by invitation</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>The Children's Hospital at Westmead - Westmead</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sydney Children's Hospitals Network</primarysponsorname>
    <primarysponsoraddress>The Children's Hospital at Westmead
Locked Bag 4001
westmead   NSW   2145</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Vertex Pharmaceuticals (partial funding) </fundingname>
      <fundingaddress>Vertex Pharmaceuticals
50 Northern Avenue
Boston, MA 02210 
</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Examine the effect of twice daily administration of 150mg ivacaftor on exocrine pancreatic function of patients with cystic fibrosis and at least one copy of the G551D CFTR mutation</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney Children's Hospitals Network Human Research Ethics Committee</ethicname>
      <ethicaddress>Locked bag 4001
WESTMEAD   NSW   2145</ethicaddress>
      <ethicapprovaldate>20/12/2013</ethicapprovaldate>
      <hrec>230</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Kevin Gaskin</name>
      <address>James Fairfax Institute of Paediatric Nutrition
The Children's Hospital at Westmead
Locked Bag 4001
Westmead   NSW   2145</address>
      <phone>+61 2 98450000</phone>
      <fax />
      <email>kevin.gaskin@health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Karen McKay</name>
      <address>The Children's Hospital at Westmead
Locked Bag 4001
Westmead   NSW   2145</address>
      <phone>+61 2 98450000</phone>
      <fax />
      <email>karen.mckay@health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Karen McKay</name>
      <address>The Children's Hospital at Westmead
Locked Bag 4001
Westmead   NSW   2145</address>
      <phone>+61 2 98450000</phone>
      <fax />
      <email>karen.mckay@health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>